Clinical trial
Aldara for the Treatment of Large and/or Multiple sBCC
NCT00189280 · MEDA Pharma GmbH & Co. KG, Industry · Completed
Key facts
| NCT number | NCT00189280 |
|---|---|
| Title | Aldara for the Treatment of Large and/or Multiple sBCC |
| Official title | Open Study to Evaluate the Efficacy and Tolerance of Imiquimod 5% Cream for the Treatment of a Large and/or Multiple Superficial Basal Cell Carcinoma. |
| Lead sponsor | MEDA Pharma GmbH & Co. KG, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Basal Cell |
| Intervention type | Drug |
| Interventions | Imiquimod |
| Enrollment | 111 |
| Start date | May 1, 2003 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | Feb 22, 2022 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: